Protalix BioTherapeutics to Report First Quarter Financials
Protalix BioTherapeutics, Inc. (NYSE American: PLX) is poised to announce its financial results for the first quarter of 2025, including insights into its business operations and clinical advancements. This information will be presented on May 9, 2025, during a dedicated conference call and webcast.
Conference Call to Discuss Results
Management is eager to engage with stakeholders and will lead a conference call to delve into the financial results. Participants can expect updates on key corporate initiatives and recent regulatory movements that are shaping the future of the company.
Details of the Conference Call
The conference call is scheduled for May 9, 2025, at 8:30 a.m. Eastern Daylight Time (EDT). Interested individuals can join using the following numbers:
- Toll Free: 1-877-423-9813
- International: 1-201-689-8573
- Israeli Toll Free: 1-809-406-247
Additionally, the conference ID is 13753682, which participants will need to access the call efficiently.
Webcast Participation
Those unable to join the call can still participate through the webcast. Details to access the webcast include:
- Company Link: Visit the investor relations section on the Protalix website for updates.
- Webcast Link: Participants can join by accessing the specified webcast link.
As a reminder, it’s advisable for attendees to log in at least 15 minutes before the start time to ensure a smooth experience.
About Protalix BioTherapeutics, Inc.
Protalix is a pioneering biopharmaceutical company that specializes in developing and commercializing recombinant therapeutic proteins utilizing its innovative ProCellEx plant cell-based protein expression system. As a trailblazer in the industry, Protalix was the first to secure U.S. Food and Drug Administration (FDA) approval for a product produced through this unique plant cell method.
The company has established noteworthy partnerships, including its collaboration with Pfizer Inc., granting them the worldwide rights to taliglucerase alfa, which treats Gaucher disease. Protalix maintains manufacturing rights in select regions and continues to expand its portfolio.
Elfabrio, Protalix's second notable product, received FDA and European Medicines Agency approval, further cementing its reputation for developing effective therapeutic solutions.
In addition to successful product launches, Protalix boasts a robust development pipeline with several candidates targeting significant medical needs. This includes PRX–115, intended for treating uncontrolled gout, and PRX–119, aimed at addressing diseases related to NETs.
Investor Contact Information
For investor inquiries, reach out to Mike Moyer, Managing Director at LifeSci Advisors. He is available at +1-617-308-4306 for discussions involving investment opportunities or financial details.
Frequently Asked Questions
When will Protalix report its Q1 2025 financial results?
Protalix is scheduled to report these results on May 9, 2025.
How can I participate in the conference call?
Participants can join the call by dialing the toll-free or international numbers provided, using the conference ID 13753682.
What products has Protalix developed?
Protalix has developed products such as taliglucerase alfa for Gaucher disease and Elfabrio, which have received regulatory approval.
How can I access the webcast?
The webcast can be accessed by visiting Protalix's investor relations section on their website or through the direct webcast link on the day of the event.
Who can I contact for investor relations?
Mike Moyer, Managing Director at LifeSci Advisors, is the contact for investor relations and can be reached at +1-617-308-4306.
